RxDoctor Payments Data

James Kim, MD

Ophthalmology · Bellingham, WANPI 1144203043

Payments from drug & device makers

$1,258in general payments, 2019–2025

Across 56 payments — averaging $22.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$372
  • Alcon$257
  • Ivantis, Inc$165
  • Novartis$120
  • Amgen$56
  • Bausch & Lomb Americas Inc.$38
  • plus $249 from 10 others

What the payments were for

  • Consulting fees$15012%
  • Food & beverage$1,06885%
  • Education$403%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,258 in reported general payments places this provider in the 55th percentile of 428 ophthalmology providers in Washington.

See all ophthalmology providers in Washington

Medicare billing

Part B allowed, 2024
$268,423
Medicare patients
831
Services billed
2,351

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast75$85,538
RestasisCyclosporine89$81,364
LumiganBimatoprost101$42,535
RocklatanNetarsudil Mesylat/Latanoprost51$22,326
Cyclosporine48$16,291
Alphagan PBrimonidine Tartrate25$12,397
IlevroNepafenac30$12,255
CombiganBrimonidine Tartrate/Timolol36$9,686
Latanoprost809$9,170
Prednisolone Acetate260$8,964
Bromfenac Sodium52$7,430
RhopressaNetarsudil Mesylate19$7,203
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat301$5,330
SimbrinzaBrinzolamide/Brimonidine Tart12$4,786
Ketorolac Tromethamine151$4,643

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P, Combigan$372$145,981251 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$38$88,85186 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$20$29,52970 claims
NovartisIlevro$120$12,25530 claims
AlconSimbrinza$257$4,78612 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$25$3,17121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 428 ophthalmology providers in Washington.

Other ophthalmology in Bellingham

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →